Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight

Inclusion Criteria:

* Body mass index (BMI) ≥ 30 kilograms per meter square (kg/m\^2), or BMI ≥ 27 to \< 30 kg/m\^2 with one of the following:

  * hypertension: treated, or with systolic blood pressure ≥ 130 millimeters of mercury (mmHg) or diastolic blood pressure ≥ 80 mmHg
  * dyslipidemia: treated or previously diagnosed high cholesterol, high triglycerides, or low HDL cholesterol.
  * history of obstructive sleep apnea
  * history of cardiovascular disease
  * history of fatty liver disease (including metabolic dysfunction-associated steatotic liver disease \[MASLD\] or metabolic dysfunction-associated steatohepatitis \[MASH\])
* At least 1 unsuccessful attempt at weight loss by diet and exercise.
* Contraception for females.
* Willingness to follow trial procedures for the duration of the trial.

Exclusion Criteria:

* Obesity induced by other endocrinologic disorders.
* Change in body weight \> 5 kg within last 90 days.
* Previous or planned surgical, endoscopic, or device-based treatment for obesity.
* History of malignancy within the past 5 years.
* Type 1 or Type 2 diabetes mellitus.
* History of chronic pancreatitis or history of acute pancreatitis within last 180 days.
* Family or personal history of medullary thyroid cancer.
* Previous participation in a Maridebart Cafraglutide trial.